Several research groups are studying Selleckchem Everolimus donor treatment and it may be applied clinically in the near future. However, our experimental model could not be transferred directly to a cadaveric donor transplant model, because brain death of the donor has not been considered. Brain death is a strong proinflammatory event that results in the activation of several pathways [54].

However, we believe that the model could be clinically useful for those patients with living donors who require prolonged bench surgery, or for those patients included in donor pair programmes requiring a longer time of cold ischaemia. As there is no evidence of immunosuppression to donors in living donors, this issue should be debated within a bioethical framework. To our knowledge, this is one of the few studies showing evidence of a lower I/R injury with combined immunosuppressive treatment of donors using a syngeneic rat model. The use of immunosuppressive drugs administered Wnt activity to donors has attenuated

the I/R injury process and this was demonstrated by a marked necrosis and apoptosis decrease in renal tubular epithelial cells. Further studies based on this exploratory study would describe the use of immunosuppressive treatment to the donor to improve the quality of the organ to be transplanted. The authors thank Professor Dr Enrique Portiansky for his assistance in the quantification of optical densities and areas of IHC. The authors of this manuscript have no conflicts Y-27632 cell line of interest to disclose. “
“Secretory proteins of Mycobacterium tuberculosis are the major immunomodulators of the host immune response. Open reading frame (ORF) Rv2626c, encoding a conserved hypothetical protein eliciting a strong humoral immune response in patients with tuberculosis (TB), was shown to be up-regulated upon infection in mice under hypoxic conditions. We now show that recombinant Rv2626c protein (rRv2626c) can bind to the surface of murine macrophages and elicit the type-1 immune response, as manifested by nitric oxide (NO) secretion and expression of inducible nitric oxide synthase (iNOS). Significant induction of pro-inflammatory

cytokines [interleukin (IL)-12 and tumour necrosis factor (TNF)-α] was evident upon stimulation of murine macrophages, as well as peripheral blood mononuclear cells (PBMCs) isolated from patients with active TB disease, with rRv2626c. Stimulation with rRv2626c also enhanced the expression of costimulatory molecules such as B7-1, B7-2 and CD40 on murine macrophages. We further show that the production of NO and pro-inflammatory cytokines in response to rRv2626c is mediated by the transcription factor nuclear factor (NF)-κB, and this was further confirmed using pyrrolidine dithiocarbamate (PDTC), a specific pharmacological inhibitor of NF-κB. Rv2626c therefore appears to modulate macrophage effector functions by eliciting both innate and adaptive immune responses, suggesting its possible use as a vaccine candidate.